First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Rival BTK degraders face off in CLL patients naive to BTK inhibition.
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
What could be the four HengRui assets picked up by Bristol?
GDC-1261 and INR731 enter phase 1, but how do they act?
